PROJECT SUMMARY
Choroidal neovascularization (CNV), the wet type of age-related macular degeneration (AMD), is a major
cause of blindness in the elderly. Current anti-vascular endothelial growth factor (VEGF) therapy has a number
of serious limitations including: 1) many patients respond poorly or not at all to mono anti-VEGF treatments
(non-responders); 2) the long-term outcomes are suboptimal even for responders and can lead to anti-VEGF
resistance; 3) repetitive intravitreal injections adversely affect quality of life and increase the risk of local
complications. Therefore, alternative or combination therapies to improve CNV treatment efficacy represent a
major unmet clinical need. Anti-VEGF resistance in CNV patients is frequently associated with arteriolar CNV
(large-caliber branching arterioles, vascular loops and anastomotic connections), in which macrophages are
known to play important roles, whereas anti-VEGF responders are characterized by capillary CNV, in which
VEGFR2 signaling has an overriding role. The secretory apolipoprotein A-I (apoA-I) binding protein (AIBP)
binds to its partner apoA-I or high-density lipoprotein (HDL) to enhance cholesterol efflux and inhibit lipid raft-
anchored VEGFR2 signaling in hyperactive endothelial cells. By binding the toll-like receptor 4 (TLR4), AIBP
augments cholesterol efflux from macrophages, thereby suppressing inflammation (Fig. 1). VEGF is an
inflammatory cytokine that recruits macrophages to vascular sites of inflammation where heightened secretion
of additional VEGF and other pro-angiogenic factors by macrophages creates positive feedback loops. We
hypothesize that combinations of AIBP, apoA-I and anti-VEGF will combat anti-VEGF resistance by
simultaneously targeting VEGF, endothelial cells, and macrophages. We recently showed that this combination
therapy was effective in treating anti-VEGF resistance by potently inhibiting arteriolar CNV, whereas aflibercept
monotherapy was ineffective (IOVS, 2022). Our objective is to develop AIBP/apoA-I/anti-VEGF combination
gene therapy with broad application and long-term efficacy for AMD, thereby obviating the limitations of current
Aim1 will determine the role of AIBP in pathological angiogenesis. Aim 2 will test the hypothesis that targeting
macrophages with AIBP is necessary to overcome anti-VEGF resistance in CNV by combination therapy. Aim
3 will develop long-term AIBP/apoA-I/anti-VEGF combination gene therapy for CNV in mouse AMD models.